Cytomegalovirus Retinitis D017726

Related MeSH Hierarchy (5)

Diseases [C] » Infections [C01] » Eye Infections » Eye Infections, Viral » Cytomegalovirus Retinitis

Diseases [C] » Infections [C01] » Virus Diseases » DNA Virus Infections » Herpesviridae Infections » Cytomegalovirus Infections » Cytomegalovirus Retinitis

Diseases [C] » Infections [C01] » Virus Diseases » Eye Infections, Viral » Cytomegalovirus Retinitis

Diseases [C] » Eye Diseases [C11] » Eye Infections » Eye Infections, Viral » Cytomegalovirus Retinitis

Diseases [C] » Eye Diseases [C11] » Retinal Diseases » Retinitis » Cytomegalovirus Retinitis

Description

Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.   MeSH

Hierarchy View

View MeSH Tree

Approved Indicated Drugs (3)

cidofovir (vistide)

foscarnet (foscavir)

ganciclovir (cytovene)

Phase 4 Indicated Drugs (1)

procaine benzylpenicillin (novocaine)

Phase 3 Indicated Drugs (2)

sargramostim (leukine)

valganciclovir (Valcyte)

Phase 2 Indicated Drugs (2)

fomivirsen sodium (vitravene)

nelfinavir (viracept)

Phase 1 Indicated Drugs (1)

aldesleukin (Proleukin)

Other Experimental Indicated Drugs (4)

aciclovir (zovirax)

immune globulin (human) (Gamastan)

interferon beta-1b (betaseron)

zidovudine (retrovir)


Organization Involved with Phase 4 Indications (2)

Astra

National Institute of Allergy and Infectious Diseases (NIAID)

Organization Involved with Phase 3 Indications (20)

Baylor University

Cornell University

Icahn School of Medicine at Mount Sinai

Johns Hopkins University

Louisiana State University

National Eye Institute (NEI)

New York Presbyterian Hospital

New York University

Northwestern University

Rutgers University

Schering-Plough

Tulane University

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Massachusetts

University of Miami

University of North Carolina at Chapel Hill

University of South Florida

University of Wisconsin

Organization Involved with Phase 2 Indications (4)

Agouron

Facet Biotech

Ionis Pharmaceuticals, Inc.

National Center for Research Resources (NCRR)

Organization Involved with Phase 1 Indications (2)

Chiron

Sandoz

Organization Involved with Other Experimental Indications (2)

American National Red Cross

Anderson Clinical Research

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.